Prospective study of effects of endogenous estrogens on myocardial no-reflow risk in postmenopausal women with acute myocardial infarction

Journal of Interventional Cardiology

Volumn 27, Issue 5, 2014, Pages 437-443

  Dong, Mei ^a   Mu, Nan ^a   Ren, Faxin ^a   Sun, Xiaojian ^a   Li, Fengli ^a   Zhang, Chuanhuan ^a   Yang, Jun ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; ESTRONE; SEX HORMONE BINDING GLOBULIN;

ADULT; ANGIOCARDIOGRAPHY; BLOOD SAMPLING; CARDIOVASCULAR EFFECT; CORONARY RISK; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; POSTMENOPAUSE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS; BLOOD; COMPLICATION; CORONARY ARTERY THROMBOSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; NO REFLOW PHENOMENON;

C-REACTIVE PROTEIN; CORONARY THROMBOSIS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; POSTMENOPAUSE; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN;

EID: 84908539940     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12137     Document Type: Review

References (35)

1. Mendelsohn ME, Karas RH., The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
2. Izadnegahdar M, Norris C, Kaul P, et al. Basis for sex-dependent outcomes in acute coronary syndrome. Can J Cardiol 2014; pii: S0828-282X(13)01395-0. doi: 10.1016/j.cjca.2013.08.020 [Epub ahead of print].
3. Abdel-Qadir HM, Ivanov J, Austin PC, et al. Sex differences in the management and outcomes of Ontario patients with cardiogenic shock complicating acute myocardial infarction. Can J Cardiol 2013; 29: 691-696. doi: 10.1016/j.cjca.2012.09.020. Epub 2012 Dec 21.
4. Vickers MR, Maclennan AH, Lawton B, et al. Main morbidities recorded in the Women's International Study of Long Duration Oestrogen After Menopause (WISDOM): A randomized controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335: 239-244.
5. Rezkalla SH, Kloner RA., Coronary no-reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008; 72: 950-957.
6. Tanriverdi H, Evrengul H, Kilic ID, et al. Aortic pressures, stiffness and left ventricular function in coronary slow flow phenomenon. Cardiology 2010; 116: 261-267.
7. Dong M, Guo F, Yang J, et al. Detrimental effects of endogenous oestrogens on primary acute myocardial infarction among postmenopausal women. Neth Heart J 2013; 21: 175-180.
8. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
9. Funayama H, Ishikawa SE, Kubo N, et al. Close association of regional interleukin-6 levels in the infarct-related culprit coronary artery with restenosis in acute myocardial infarction. Circ J 2006; 70: 426-429.
10. de Boer MJ, Reiber JHC, Suryapranata H, et al. Angiographic findings and catheterisation laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction. Eur Heart J 1995; 16: 1347-1356.
11. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis in Myocardial Infarction (TIMI) Study Group. Circulation 1999; 99: 1945-1950.
12. van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.
13. Gibson CM, Murphy SA, Morrow DA, et al. Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J 2004; 148: 336-340.
14. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: The AMISTAD-2 trial. Eur Heart J 2006; 27: 2400-2405.
15. Niccoli G, Giubilato S, Russo E, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008; 29: 1843-1850.
16. Rezkalla SH, Kloner RA., No-reflow phenomenon. Circulation 2002; 105: 656-662.
17. Barrett-Connor E, Goodman-Gruen D., Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995; 311: 1193-1196.
18. Price JF, Lee AJ, Fowkes FG., Steroid sex hormones and peripheral arterial disease in the Edinburgh Artery Study. Steroids 1997; 62: 789-794.
19. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
20. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-1477.
21. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med 2006; 166: 357-365.
22. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591-2602.
23. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001; 104: 1773-1778.
24. Herkert O, Kuhl H, Sandow J, et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of the glucocorticoid receptor. Circulation 2001; 104: 2826-2831.
25. Booth EA, Lucchesi BR., Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17β-estradiol in an in vivo model of myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2007; 293: H1408-H1415.
26. Dubey RK, Imthurn B, Barton M, et al. Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovasc Res 2005; 66: 295-306.
27. Dubey RK, Jackson EK, Delbert G, et al. Medroxyprogesterone abrogates the inhibitory effects of estradiol on vascular smooth muscle cells by preventing estradiol metabolism. Hypertension 2008; 51: 1197-1202.
28. Liu Y, Ding J, Bush TL, et al. Relative androgen excess and increased cardiovascular risk after menopause: A hypothesized relation. Am J Epidemiol 2001; 154: 489-494.
29. 4) to cardiovascular risk factors in postmenopausal women. Am J Epidemiol 1995; 142: 925-934.
30. Guo F, Dong M, Ren F, et al. Association between local interleukin-6 levels and slow flow/microvascular dysfunction. J Thromb Thrombolysis 2014; 374: 475-482.
31. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-722.
32. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-716.
33. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of estrogen and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001; 86: 4216-4222.
34. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
35. Pasceri V, Willerson JT, Yeh ETH., Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.